Gene therapy: A possible future standard for HIV care

Trends in Biotechnology

Volumn 33, Issue 7, 2015, Pages 374-376

  Abou El Enein, Mohamed ^a   Bauer, Gerhard ^b   Reinke, Petra ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GENE THERAPY AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMMERCIAL PHENOMENA; COST CONTROL; DRUG COST; DRUG INDUSTRY; ERADICATION THERAPY; EXPECTATION; FUNDING; GENE THERAPY; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INTERPERSONAL COMMUNICATION; MEDICALLY UNINSURED; NOTE; PHYSICIAN; PRIORITY JOURNAL; PROFIT; SOCIAL BEHAVIOR; DISEASE ERADICATION; HIV INFECTIONS;

DISEASE ERADICATION; GENETIC THERAPY; HIV INFECTIONS; HUMANS;

EID: 84930892969     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2015.03.006     Document Type: Note

References (17)

1. Piot P., Quinn T.C. Response to the AIDS pandemic: a global health model. N. Engl. J. Med. 2013, 368:2210-2218.
2. Sloan C.E., et al. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS 2012, 26:45-56.
3. Hoxie J.A., June C.H. Novel cell and gene therapies for HIV. Cold Spring Harb. Perspect. Med. 2012, 2:10.
4. Deakin C.T., et al. Accepting risk in clinical research: is the gene therapy field becoming too risk-averse?. Mol. Ther. 2009, 17:1842-1848.
5. Stangl, A.L. and Grossman, C.I., eds (2013) Global action to reduce HIV stigma and discrimination. J. Int. AIDS Soc. Published November 13, 2013. doi:10.7448/IAS.16.3.18934.
6. Slingsby B.T., Kurokawa K. The Global Health Innovative Technology (GHIT) Fund: financing medical innovations for neglected populations. Lancet Glob. Health 2013, 1:e184-e185.
7. Lu C., et al. Absorptive capacity and disbursements by the Global Fund to fight AIDS, tuberculosis and malaria: analysis of grant implementation. Lancet 2006, 368:483-488.
8. Sax P.E., et al. HIV cure strategies: how good must they be to improve on current antiretroviral therapy?. PLoS ONE 2014, 9:e113031.
9. Abou-El-Enein M., et al. The business case for cell and gene therapies. Nat. Biotechnol. 2014, 32:1192-1193.
10. Abou-El-Enein M., et al. A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends Mol. Med. 2014, 20:632-642.
11. Hoofnagle J.H., Sherker A.H. Therapy for hepatitis C: the costs of success. N. Engl. J. Med. 2014, 370:1552-1553.
12. Hill A., et al. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin. Infect. Dis. 2014, 58:928-936.
13. Plahte J. Tiered pricing of vaccines: a win-win-win situation, not a subsidy. Lancet Infect. Dis. 2005, 5:58-63.
14. 1 July News (2014) Clin. Infect. Dis. 59, i-ii. doi:10.1093/cid/ciu317.
15. Liao H.-K., et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat. Commun. 2015, 6:6413.
16. Arcidiacono J.A., et al. US Food and Drug Administration international co-llaborations for cellular therapy product regulation. Stem Cell Res. Ther. 2012, 3:38.
17. Smith S.E., Reeder S.J. What nurse practitioners should know about gene therapy. Nurse Pract. 2013, 38:16-22. quiz 22-23.